Merck Stock Seen Undervalued Despite Cancer Trial Progress
Merck's stock has seen significant gains over the past few years but its valuation signals are mixed. According to a Discounted Cash Flow (DCF) analysis, the shares trade about 38.8% below their intrinsic value, estimated at around $235 per share.
The DCF model takes into account Merck's projected cash flows and assumes they will level off gradually over the next decade. This estimate implies that the stock is undervalued relative to its future cash generation potential.
However, other market multiples such as P/E ratio suggest that the shares are already carrying a premium, trading at around 111.9x earnings compared to a pharmaceuticals sector average of 16.0x and a peer group average of 29.5x.
The company's pipeline and product news flow may have contributed to its recent share gains, but the DCF analysis suggests that there is still room for further upside in the longer run.